<DOC>
	<DOCNO>NCT00994292</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy various dos YM150 ( experimental drug ) prevention ischemic vascular event subject recent acute coronary syndrome .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability Efficacy YM150 Subjects With Acute Coronary Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>diagnosis STEACS , NSTEACS index event accord accept guideline ESC AHA guideline elevate cardiac biomarkers plan myocardial revascularization ( e.g. , Coronary Artery Bypass Graft ( CABG ) elective stag PCI ) invasive procedure increase risk bleeding ( i.e . elective surgical procedure ) within 60 day randomization recent stroke TIA â‰¤ 12 month prior index event persistent BP 160 mmHg systolic high and/or 100 mmHg diastolic high baseline without medication participate another clinical trial investigational drug ( include placebo ) device within 30 day ( limit set national law , whichever long ) signing inform consent present study participate YM150 clinical trial require ongoing parenteral oral anticoagulant therapy active bleeding opinion investigator high risk bleeding study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Factor Xa</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>YM150</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
</DOC>